Eupraxia Pharmaceuticals Inc.(EPRX)Earnings, Financials & Key Ratios
EPRX•NASDAQ
$7.47
$250M mkt cap·Price updated May 7, 2026
AboutEupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.Show more
- Revenue$0
- EBITDA-$39M-0.6%
- Net Income-$39M-6.9%
- EPS (Diluted)-1.05-38.2%
- ROE-69.99%+68.8%
- ROIC-79478.84%
- Debt/Equity0.00-15.0%
EPRX Key Insights
Eupraxia Pharmaceuticals Inc. (EPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 57.8% over 5 years
- ✗Shares diluted 17.8% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
EPRX Price & Volume
Eupraxia Pharmaceuticals Inc. (EPRX) stock price & volume — 10-year historical chart
Loading chart...
EPRX Growth Metrics
Eupraxia Pharmaceuticals Inc. (EPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-42.94%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-61.84%
Return on Capital
10 Years-181.88%
5 Years-198.98%
3 Years-184.32%
Last Year-69.68%
EPRX Recent Earnings
Eupraxia Pharmaceuticals Inc. (EPRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (9%)
Q2 2026Latest
Mar 12, 2026EPS
$0.37
Est $0.16
-131.3%
Revenue
—
Q4 2025
Nov 4, 2025EPS
$0.19
Est $0.23
+17.4%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.26
Est $0.21
-23.8%
Revenue
—
Q2 2025
May 6, 2025EPS
$0.21
Est $0.19
-10.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.37vs $0.16-131.3% | — |
| Q4 2025 | Nov 4, 2025 | $0.19vs $0.23+17.4% | — |
| Q3 2025 | Aug 12, 2025 | $0.26vs $0.21-23.8% | — |
| Q2 2025 | May 6, 2025 | $0.21vs $0.19-10.5% | — |
Based on last 12 quarters of dataView full earnings history →
EPRX Peer Comparison
Eupraxia Pharmaceuticals Inc. (EPRX) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PACB | 498.3M | 1.65 | -0.91 | 3.89% | -341.47% | -11.23% | 141.98 | |
 IRWD | 679.95M | 4.17 | 27.80 | -15.72% | 41.76% | |||
 PTGX | 6.36B | 98.85 | -48.22 | -89.41% | -6.48% | -17.76% | 0.02 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PCRX | 929.88M | 23.64 | 147.75 | 3.63% | 1.27% | 1.31% | 0.66 | |
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 PFE | 150.63B | 26.48 | 19.47 | -1.65% | 11.83% | 8.34% | 0.78 |
Compare EPRX vs Peers
Eupraxia Pharmaceuticals Inc. (EPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EPRX Income Statement
Eupraxia Pharmaceuticals Inc. (EPRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 86.62K | 125.43K | 207.44K | 117.07K | 0 | 0 | 0 | 0 | 241.68K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -86.62K▲ 0% | -125.43K▼ 44.8% | -207.44K▼ 65.4% | -117.07K▲ 43.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -241.68K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -44.8% | -65.39% | 43.56% | 100% | - | - | - | - |
| Operating Expenses | 4.84M | 11.9M | 6.62M | 2.36M | 14.65M | 17.62M | 27.85M | 38.83M | 38.83M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.48M | 5.1M | 3.1M | 1.27M | 6.97M | 3.99M | 7.48M | 15.71M | 17.34M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.36M | 6.8M | 3.52M | 1.09M | 7.59M | 13.63M | 20.36M | 23.12M | 21.49M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 1.74K | 0 | 87.47K | 0 | 0 | 0 | 0 |
| Operating Income | -4.93M▲ 0% | -12.02M▼ 144.1% | -6.82M▲ 43.2% | -2.47M▲ 63.7% | -14.65M▼ 492.0% | -17.62M▼ 20.3% | -27.85M▼ 58.1% | -38.83M▼ 39.5% | -39.07M▼ 0.6% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -144.06% | 43.25% | 63.73% | -491.98% | -20.26% | -58.07% | -39.45% | -0.62% |
| EBITDA | -4.84M | -11.9M | -6.62M | -2.36M | -14.56M | -17.47M | -27.69M | -38.59M | -38.83M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -145.84% | 44.39% | 64.36% | -517.67% | -19.97% | -58.51% | -39.34% | -0.64% |
| D&A (Non-Cash Add-back) | 86.62K | 125.43K | 207.44K | 117.07K | 87.47K | 147.89K | 155.53K | 246.95K | 241.68K |
| EBIT | -5.02M | -14.64M | -5.93M | -2.13M | -17.31M | -18.01M | -27.76M | -36.15M | -39.07M |
| Net Interest Income | -52.48K | -141.07K | -1.45M | -1.88M | -965.44K | -551.06K | -307.2K | 800.11K | 1.44M |
| Interest Income | 330 | 1.11K | 12.04K | 427 | 51.55K | 431.8K | 862.97K | 1.67M | 1.44M |
| Interest Expense | 52.81K | 142.17K | 1.46M | 1.88M | 1.02M | 982.86K | 1.17M | 867.99K | 0 |
| Other Income/Expense | -145.22K | -2.76M | -615.22K | -1.55M | -3.68M | -1.37M | -1.08M | 1.81M | -155.06K |
| Pretax Income | -5.07M▲ 0% | -14.79M▼ 191.6% | -7.44M▲ 49.7% | -4.02M▲ 46.0% | -18.33M▼ 356.0% | -18.99M▼ 3.6% | -28.93M▼ 52.3% | -37.02M▼ 28.0% | -39.23M▼ 6.0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 36.42K | 2.59K | 19.41K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -0.13% | -0.01% | -0.05% |
| Net Income | -4.38M▲ 0% | -13.19M▼ 201.1% | -7.37M▲ 44.1% | -4.01M▲ 45.7% | -18.03M▼ 350.1% | -18.49M▼ 2.5% | -28.22M▼ 52.6% | -36.67M▼ 30.0% | -39.22M▼ 6.9% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -201.09% | 44.11% | 45.65% | -350.07% | -2.54% | -52.63% | -29.96% | -6.94% |
| Net Income (Continuing) | -5.07M | -14.79M | -7.44M | -4.02M | -18.33M | -18.99M | -28.97M | -37.02M | -39.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -871.66K | -376.02K | -440.45K | -453.89K | -833.84K | -783.49K | -1.32M | -1.57M | -1.59M |
| EPS (Diluted) | -0.34▲ 0% | -1.03▼ 202.9% | -0.56▲ 45.6% | -0.31▲ 44.6% | -1.61▼ 419.4% | -0.96▲ 40.4% | -1.17▼ 21.9% | -0.76▲ 35.0% | -1.05▼ 38.2% |
| EPS Growth % | - | -202.94% | 45.63% | 44.64% | -419.35% | 40.37% | -21.88% | 35.04% | -38.16% |
| EPS (Basic) | -0.34 | -1.03 | -0.56 | -0.31 | -1.61 | -0.96 | -1.17 | -0.76 | -1.05 |
| Diluted Shares Outstanding | 12.87M | 12.87M | 12.87M | 12.87M | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Basic Shares Outstanding | 12.87M | 12.87M | 12.87M | 12.87M | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
EPRX Balance Sheet
Eupraxia Pharmaceuticals Inc. (EPRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.42M | 2.47M | 2.64M | 1.14M | 30.6M | 25.17M | 19.8M | 34.44M | 84.87M |
| Cash & Short-Term Investments | 3.99M | 823.48K | 1.16M | 150.13K | 29.9M | 24.73M | 19.34M | 33.1M | 80.35M |
| Cash Only | 3.99M | 823.48K | 1.16M | 150.13K | 20.89M | 24.73M | 19.34M | 33.1M | 80.35M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 9.01M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.04M | 1.09M | 0 | 0 | 0 | 0 | 190.61K | 228.87K | 672.45K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 120.82K | 166.75K | 1.35M | 620.61K | 429.72K | 121.47K | 0 | 0 | 1.04M |
| Total Non-Current Assets | 419.44K | 435.47K | 646.21K | 315.34K | 620.44K | 721.98K | 463.15K | 505.68K | 1.05M |
| Property, Plant & Equipment | 419.44K | 435.47K | 646.21K | 315.34K | 589.07K | 718.61K | 456.25K | 424.92K | 984.52K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 31.37K | 3.37K | 6.9K | 80.76K | 64.16K |
| Total Assets | 5.84M▲ 0% | 2.91M▼ 50.2% | 3.29M▲ 12.9% | 1.45M▼ 55.8% | 31.22M▲ 2047.9% | 25.89M▼ 17.1% | 20.27M▼ 21.7% | 34.94M▲ 72.4% | 85.92M▲ 145.9% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | - | -50.2% | 12.92% | -55.75% | 2047.93% | -17.08% | -21.72% | 72.42% | 145.9% |
| Total Current Liabilities | 730.68K | 14.34M | 20.67M | 22.54M | 2.27M | 4.14M | 19.37M | 3.1M | 5.61M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 3.79M | 11.63M | 12.52M | 94.92K | 107.53K | 10.4M | 0 | 78.25K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 440.65K | 5.33M | 6.8M | 6.94M | 5.01K | 21.66K | 858.63K | 1.49M | 3.92M |
| Current Ratio | 7.42x | 0.17x | 0.13x | 0.05x | 13.49x | 6.08x | 1.02x | 11.10x | 15.12x |
| Quick Ratio | 7.42x | 0.17x | 0.13x | 0.05x | 13.49x | 6.08x | 1.02x | 11.10x | 15.12x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.13K | 0 | 749.35K | 574.97K | 9.84M | 11.99M | 0 | 0 | 75.71K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 9.7M | 11.92M | 0 | 0 | 0 |
| Capital Lease Obligations | 4.08K | 0 | 251.19K | 198.66K | 137.75K | 69.46K | 0 | 0 | 75.71K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.05K | 0 | 498.15K | 376.31K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 735.82K | 14.34M | 21.42M | 23.12M | 12.1M | 16.13M | 19.37M | 3.1M | 5.69M |
| Total Debt | 12.47K | 3.79M | 11.94M | 12.77M | 9.99M | 12.17M | 10.45M | 71.86K | 153.95K |
| Net Debt | -3.98M | 2.97M | 10.78M | 12.62M | -10.9M | -12.56M | -8.89M | -33.03M | -80.2M |
| Debt / Equity | 0.00x | - | - | - | 0.52x | 1.25x | 11.71x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -95.02x | -103.00x | -4.05x | -1.13x | -17.02x | -18.32x | -23.72x | -41.65x | - |
| Total Equity | 5.11M▲ 0% | -11.44M▼ 323.9% | -18.13M▼ 58.6% | -21.66M▼ 19.5% | 19.12M▲ 188.2% | 9.76M▼ 49.0% | 892.33K▼ 90.9% | 31.84M▲ 3468.1% | 80.23M▲ 152.0% |
| Equity Growth % | - | -323.94% | -58.55% | -19.49% | 188.25% | -48.95% | -90.86% | 3468.09% | 152% |
| Book Value per Share | 0.40 | -0.89 | -1.41 | -1.68 | 1.34 | 0.51 | 0.04 | 0.94 | 2.01 |
| Total Shareholders' Equity | 5.98M | -11.06M | -17.69M | -21.21M | 19.95M | 10.54M | 2.22M | 33.4M | 81.83M |
| Common Stock | 23.59M | 23.55M | 23.55M | 23.8M | 77.65M | 96.13M | 92.91M | 116.36M | 194.89M |
| Retained Earnings | -20.11M | -40.02M | -47.2M | -51.2M | -74.26M | -104.63M | -105.5M | -131M | -169.13M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 16.56M | -3.77M | -2.71M | -4.16M | -2.04M |
| Minority Interest | -871.66K | -376.02K | -440.45K | -453.89K | -833.84K | -783.49K | -1.32M | -1.57M | -1.59M |
EPRX Cash Flow Statement
Eupraxia Pharmaceuticals Inc. (EPRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.3M | -8.32M | -5.17M | -403.78K | -11.58M | -14.4M | -20.75M | -29.99M | -29.03M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -57.05% | 37.85% | 92.19% | -2766.8% | -24.36% | -44.14% | -44.56% | 3.22% |
| Net Income | -5M | -14.83M | -7.18M | -4M | -18.18M | -18.99M | -28.97M | -25.74M | -39.22M |
| Depreciation & Amortization | 85.38K | 125.83K | 201.94K | 116.81K | 88.17K | 147.89K | 155.53K | 171.72K | 241.68K |
| Stock-Based Compensation | 162.82K | 2.92M | 544.95K | 228.68K | 0 | 1.43M | 1.41M | 3.22M | 0 |
| Deferred Taxes | 0 | 291.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 51.17K | 2.08M | 1.09M | 2.52M | 6.68M | 1.5M | 1.3M | -880.5K | 10.68M |
| Working Capital Changes | -599.39K | 1.1M | 167.54K | 730.59K | -167.16K | 1.51M | 5.35M | -6.76M | -725.6K |
| Change in Receivables | -340.22K | -208.58K | 135.27K | 727.69K | 150.92K | 230.48K | -103.71K | -101.39K | -438.64K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 1.32M | 577.91K | -714.88K | 2.4M |
| Cash from Investing | -314.69K | -141.86K | -1.9M | 24.62K | -11.42M | 9.83M | -73.38K | -75.16K | -598.77K |
| Capital Expenditures | -314.69K | -141.86K | -9.48K | 0 | -341.28K | -235.55K | -73.38K | -104.23K | -598.77K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -1.89M | 24.62K | -3.97M | 242 | 0 | 29.07K | 0 |
| Cash from Financing | 9.47M | 5.3M | 7.4M | -626.64K | 39.46M | 10.8M | 21.08M | 45.78M | 77.33M |
| Debt Issued (Net) | 463.06K | 2.67M | 4.38M | -1.1M | 9.62M | -142.27K | -79.44K | -9.14M | 0 |
| Equity Issued (Net) | 9M | 0 | 0 | 0 | 29.91M | 10.64M | 15.89M | 54.56M | 77.33M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 2.62M | 3.02M | 474.05K | -69.33K | 306.77K | 5.27M | 363.06K | 0 |
| Net Change in Cash | 3.85M▲ 0% | -3.17M▼ 182.2% | 332.6K▲ 110.5% | -1.01M▼ 402.5% | 16.4M▲ 1730.2% | 5.73M▼ 65.0% | 1.08M▼ 81.2% | 13.76M▲ 1176.0% | 47.3M▲ 243.7% |
| Free Cash Flow | -5.61M▲ 0% | -8.46M▼ 50.8% | -5.18M▲ 38.8% | -403.78K▲ 92.2% | -11.92M▼ 2851.3% | -14.63M▼ 22.8% | -20.82M▼ 42.3% | -30.1M▼ 44.6% | -29.63M▲ 1.6% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -50.77% | 38.78% | 92.21% | -2851.32% | -22.77% | -42.32% | -44.55% | 1.57% |
| FCF per Share | -0.44 | -0.66 | -0.40 | -0.03 | -0.84 | -0.76 | -0.86 | -0.89 | -0.74 |
| FCF Conversion (FCF/Net Income) | 1.21x | 0.63x | 0.70x | 0.10x | 0.64x | 0.78x | 0.74x | 0.82x | 0.74x |
| Interest Paid | 0 | 0 | 436.44K | 116.06K | 0 | 0 | 0 | 393.74K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPRX Key Ratios
Eupraxia Pharmaceuticals Inc. (EPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -85.79% | - | - | - | -94.31% | -128.06% | -529.9% | -224.1% | -69.99% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -488.04% | - | - | -79478.84% |
| Debt / Equity | 0.00x | - | - | - | 0.52x | 1.25x | 11.71x | 0.00x | 0.00x |
| Interest Coverage | -95.02x | -103.00x | -4.05x | -1.13x | -17.02x | -18.32x | -23.72x | -41.65x | - |
| FCF Conversion | 1.21x | 0.63x | 0.70x | 0.10x | 0.64x | 0.78x | 0.74x | 0.82x | 0.74x |
EPRX Frequently Asked Questions
Eupraxia Pharmaceuticals Inc. (EPRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Eupraxia Pharmaceuticals Inc. (EPRX) grew revenue by 0.0% over the past year. Growth has been modest.
Eupraxia Pharmaceuticals Inc. (EPRX) reported a net loss of $47.3M for fiscal year 2025.
Dividend & Returns
Eupraxia Pharmaceuticals Inc. (EPRX) has a return on equity (ROE) of -70.0%. Negative ROE indicates the company is unprofitable.
Eupraxia Pharmaceuticals Inc. (EPRX) had negative free cash flow of $29.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More EPRX
Eupraxia Pharmaceuticals Inc. (EPRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates